Date | Title | | 11/12/13 | Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical UpdateROCKVILLE, Md., Nov. 12, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported financial results for the three months and nine months ended September 30, 2013 and provided a business and clinical update.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )
"The Company reached several major milestones in the third quarter. We completed patient dosing in our Phase Ib trial to treat major depressive disorder with NSI-189, our lead small molecule compound. We also ... |
| | 10/10/13 | Dr. Eva Feldman, Principal Investigator, to Give Update on ALS Trial at American Neurological Association MeetingROCKVILLE, Md., Oct. 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase II trial testing Neuralstem's spinal cord stem cells, NSI-566, in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will speak at the American Neurological Association's (ANA) Annual Meeting in New Orleans, LA, on October 15th at 1:35 (http://www.aneuroa.org/i4a/pages/index.cfm?pageid=3752). Dr. Feldman, who is also th... |
| | 10/09/13 | University Of Michigan Health System Treats Its First Patients In Neuralstem's Phase II ALS Stem Cell TrialFirst of Five Cohorts Completed in Dose Escalation Trial
ROCKVILLE, Md., Oct. 9, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the University of Michigan Health System, in Ann Arbor, Michigan, treated its first two patients in the Phase II trial testing NSI-566 neural stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This completes the first cohort in Phase II, which is also being conducted at Emory University Hospital, in Atlanta, Georgia. Pha... |
| | 09/26/13 | Neuralstem CEO To Present At Stem Cells & Regenerative Medicine CongressTed Harada, ALS Stem Cell Trial Patient, To Talk
ROCKVILLE, Md., Sept. 26, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO, Richard Garr, will present at the Stem Cells & Regenerative Medicine Congress, on Monday, September 30 at 12:00 PM at the Hyatt Regency in Cambridge, MA (http://www.terrapinn.com/2013/stem-cells-usa-regenerative-medicine/index.stm). Mr. Garr will give an overview of Neuralstem's ongoing trial testing NSI-566 stem cells in amyotr... |
| |
|